Insider Selling: Blueprint Medicines Corp (BPMC) Insider Sells 6,775 Shares of Stock

Blueprint Medicines Corp (NASDAQ:BPMC) insider Kate Haviland sold 6,775 shares of the company’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $74.93, for a total transaction of $507,650.75. Following the transaction, the insider now owns 12,649 shares of the company’s stock, valued at approximately $947,789.57. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Blueprint Medicines Corp (NASDAQ BPMC) traded up $4.95 during mid-day trading on Wednesday, reaching $82.93. 483,874 shares of the company’s stock were exchanged, compared to its average volume of 324,370. The firm has a market cap of $3,159.17, a P/E ratio of -24.32 and a beta of 1.16. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.28 and a current ratio of 11.28. Blueprint Medicines Corp has a 12 month low of $32.43 and a 12 month high of $92.00.

Several research analysts recently weighed in on BPMC shares. JMP Securities upped their price target on shares of Blueprint Medicines from $88.00 to $97.00 and gave the stock an “outperform” rating in a research report on Monday, December 11th. ValuEngine downgraded shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Cowen restated a “buy” rating on shares of Blueprint Medicines in a research report on Friday, November 10th. BidaskClub downgraded shares of Blueprint Medicines from a “buy” rating to a “hold” rating in a research report on Wednesday, December 6th. Finally, Raymond James Financial set a $82.00 price target on shares of Blueprint Medicines and gave the stock a “buy” rating in a research report on Sunday, December 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $84.20.

A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. raised its holdings in Blueprint Medicines by 3.3% in the 4th quarter. BlackRock Inc. now owns 3,081,861 shares of the biotechnology company’s stock valued at $232,401,000 after acquiring an additional 98,581 shares during the last quarter. Lord Abbett & CO. LLC raised its holdings in Blueprint Medicines by 0.5% in the 2nd quarter. Lord Abbett & CO. LLC now owns 1,729,169 shares of the biotechnology company’s stock valued at $87,617,000 after acquiring an additional 8,903 shares during the last quarter. OppenheimerFunds Inc. raised its holdings in Blueprint Medicines by 8.4% in the 4th quarter. OppenheimerFunds Inc. now owns 1,632,006 shares of the biotechnology company’s stock valued at $123,070,000 after acquiring an additional 126,752 shares during the last quarter. Vanguard Group Inc. raised its holdings in Blueprint Medicines by 16.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,415,963 shares of the biotechnology company’s stock valued at $71,746,000 after acquiring an additional 195,517 shares during the last quarter. Finally, State Street Corp raised its holdings in Blueprint Medicines by 76.8% in the 2nd quarter. State Street Corp now owns 1,400,035 shares of the biotechnology company’s stock valued at $70,936,000 after acquiring an additional 608,296 shares during the last quarter. Institutional investors own 83.79% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/14/insider-selling-blueprint-medicines-corp-bpmc-insider-sells-6775-shares-of-stock.html.

About Blueprint Medicines

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Insider Buying and Selling by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply